Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
Carsten Saft(St. Josef-Hospital)
Cited by 29
Related Papers
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease
|Molecular Neurodegeneration|2011|134
Cannabinoids for Treatment of Dystonia in Huntington’s Disease
|Journal of Huntington s Disease|2018|74